Epic Sciences
Analyses circulating tumor cells to provide actionable data for personalized cancer therapies.
What they do
Epic Sciences develops highly sensitive cancer diagnostics that detect and characterize circulating tumor cells in blood samples. Pharmaceutical firms and laboratory oncologists purchase its platform to monitor metastatic cancer progression, detect disease recurrence, and optimize therapy selection.
The record
- Vertical
- Oncology
- Sub-segment
- Cancer screening and diagnostics
- Product type
- Diagnostics
- Stage
- Series C+
- Headquarters
- San Diego, United States
- Region
- North America
- Founded
- 2008
- Total funding
- $200M raised
Notable investors: Deerfield Management, Blue Shield of California, Domain Associates, Section 32.